Literature DB >> 16544255

Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters.

Barbara Geric1, Robert J Carman, Maja Rupnik, Christopher W Genheimer, Susan P Sambol, David M Lyerly, Dale N Gerding, Stuart Johnson.   

Abstract

Binary toxin CDT or its genes have been identified in some strains of Clostridium difficile that also produce the large clostridial toxins, toxins A and B (A+B+CDT+), including a newly recognized epidemic strain in the United States and Canada. To study the effects of binary toxin alone, we characterized 4 binary toxin CDT-positive only (A-B-CDT+) C. difficile strains. Unlike other clostridial binary toxins, binary toxin CDT required exogenous trypsin for activation. Supernatants from all A-B-CDT+ strains caused marked fluid accumulation in the rabbit ileal loop assay after concentration and trypsinization. In addition, the ileal loop response was neutralized by antisera raised against other binary toxin-producing clostridia. Challenge of clindamycin-treated hamsters with these strains resulted in colonization but not diarrhea or death. Binary toxin CDT may play an adjunctive role to toxins A and B in the pathogenesis of C. difficile-associated disease but by itself may not be sufficient to cause disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16544255     DOI: 10.1086/501368

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  66 in total

1.  Transcriptional profiling of Clostridium difficile and Caco-2 cells during infection.

Authors:  Tavan Janvilisri; Joy Scaria; Yung-Fu Chang
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

Review 2.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

3.  Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains.

Authors:  R A Stabler; D N Gerding; J G Songer; D Drudy; J S Brazier; H T Trinh; A A Witney; J Hinds; B W Wren
Journal:  J Bacteriol       Date:  2006-10       Impact factor: 3.490

4.  MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.

Authors:  Michelle M Butler; Dean L Shinabarger; Diane M Citron; Ciarán P Kelly; Sofya Dvoskin; George E Wright; Hanping Feng; Saul Tzipori; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

Review 5.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

6.  Characterization of Clostridium perfringens TpeL toxin gene carriage, production, cytotoxic contributions, and trypsin sensitivity.

Authors:  Jianming Chen; Bruce A McClane
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

Review 7.  Host response to Clostridium difficile infection: Diagnostics and detection.

Authors:  Elena A Usacheva; Jian-P Jin; Lance R Peterson
Journal:  J Glob Antimicrob Resist       Date:  2016-09-20       Impact factor: 4.035

Review 8.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014

9.  Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile.

Authors:  Jordi M Lanis; Soumitra Barua; Jimmy D Ballard
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

10.  Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria.

Authors:  Carsten Schwan; Bärbel Stecher; Tina Tzivelekidis; Marco van Ham; Manfred Rohde; Wolf-Dietrich Hardt; Jürgen Wehland; Klaus Aktories
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.